Suppr超能文献

巴雷特食管癌变的危险因素。

Risk factors for neoplastic progression in Barrett's esophagus.

机构信息

Department of Gastroenterology, Royal Albert Edward Infirmary, Wigan Lane, Wigan, Greater Manchester WN12NN, United Kingdom.

出版信息

World J Gastroenterol. 2011 Aug 28;17(32):3672-83. doi: 10.3748/wjg.v17.i32.3672.

Abstract

Barrett's esophagus (BE) confers a significant increased risk for development of esophageal adenocarcinoma (EAC), with the pathogenesis appearing to progress through a "metaplasia-dysplasia-carcinoma" (MDC) sequence. Many of the genetic insults driving this MDC sequence have recently been characterized, providing targets for candidate biomarkers with potential clinical utility to stratify risk in individual patients. Many clinical risk factors have been investigated, and associations with a variety of genetic, specific gastrointestinal and other modifiable factors have been proposed in the literature. This review summarizes the current understanding of the mechanisms involved in neoplastic progression of BE to EAC and critically appraises the relative roles and contributions of these putative risk factors from the published evidence currently available.

摘要

巴雷特食管(BE)显著增加了食管腺癌(EAC)的发病风险,其发病机制似乎是通过“化生-异型增生-癌”(MDC)序列进行的。最近已经对许多推动 MDC 序列的遗传损伤进行了描述,为候选生物标志物提供了目标,这些标志物具有潜在的临床应用价值,可以对个体患者的风险进行分层。已经研究了许多临床危险因素,并且在文献中提出了与多种遗传、特定胃肠道和其他可改变因素的关联。这篇综述总结了目前对 BE 向 EAC 肿瘤进展所涉及的机制的理解,并根据目前可用的已发表证据,批判性地评估了这些假定危险因素的相对作用和贡献。

相似文献

1
Risk factors for neoplastic progression in Barrett's esophagus.
World J Gastroenterol. 2011 Aug 28;17(32):3672-83. doi: 10.3748/wjg.v17.i32.3672.
2
MicroRNAs, development of Barrett's esophagus, and progression to esophageal adenocarcinoma.
World J Gastroenterol. 2010 Feb 7;16(5):531-7. doi: 10.3748/wjg.v16.i5.531.
3
Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
Gastroenterol Clin North Am. 2015 Jun;44(2):299-315. doi: 10.1016/j.gtc.2015.02.005. Epub 2015 Mar 31.
5
Gastroesophageal reflux disease: From heartburn to cancer.
World J Gastroenterol. 2010 Aug 14;16(30):3743-4. doi: 10.3748/wjg.v16.i30.3743.
6
[Carcinogenesis of Barrett's esophagus].
Nihon Rinsho. 2005 Aug;63(8):1357-61.
7
Histology of metaplasia and dysplasia in Barrett's esophagus.
Surg Oncol Clin N Am. 2009 Jul;18(3):411-22. doi: 10.1016/j.soc.2009.03.011.
8
Biology of Barrett's esophagus and esophageal adenocarcinoma.
Gastrointest Endosc Clin N Am. 2011 Jan;21(1):25-38. doi: 10.1016/j.giec.2010.09.011.
9
Risk factors, DNA damage, and disease progression in Barrett's esophagus.
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):620-5. doi: 10.1158/1055-9965.EPI-04-0509.
10
The pathogenesis of Barrett's metaplasia and the progression to esophageal adenocarcinoma.
Recent Results Cancer Res. 2010;182:39-63. doi: 10.1007/978-3-540-70579-6_4.

引用本文的文献

2
Clinical and Endoscopic Differences Between Patients With Barrett's Esophagus With and Without Dysplasia/Adenocarcinoma.
Cureus. 2023 Oct 1;15(10):e46323. doi: 10.7759/cureus.46323. eCollection 2023 Oct.
3
Impact of Barrett oesophagus diagnoses and endoscopies on oesophageal cancer survival in the UK: A cohort study.
Cancer Med. 2022 Feb;11(4):1160-1171. doi: 10.1002/cam4.4484. Epub 2021 Dec 16.
5
Does anti-reflux surgery disrupt the pathway of Barrett's esophagus progression to cancer?
Transl Gastroenterol Hepatol. 2018 Dec 5;3:101. doi: 10.21037/tgh.2018.11.07. eCollection 2018.
6
Should visceral fat, strictly linked to hepatic steatosis, be depleted to improve survival?
Hepatol Int. 2013 Jun;7(2):413-28. doi: 10.1007/s12072-012-9406-z. Epub 2012 Oct 26.
7
A specific A/T polymorphism in Western tyrosine phosphorylation B-motifs regulates Helicobacter pylori CagA epithelial cell interactions.
PLoS Pathog. 2015 Feb 3;11(2):e1004621. doi: 10.1371/journal.ppat.1004621. eCollection 2015 Feb.
8
Risk factors associated with Barrett's epithelial dysplasia.
World J Gastroenterol. 2014 Apr 21;20(15):4353-61. doi: 10.3748/wjg.v20.i15.4353.
9
Management strategies of Barrett's esophagus.
World J Gastroenterol. 2012 Nov 21;18(43):6216-25. doi: 10.3748/wjg.v18.i43.6216.

本文引用的文献

2
Use of proton pump inhibitors and risk of progression of Barrett's esophagus to neoplastic lesions.
Am J Gastroenterol. 2009 Oct;104(10):2646-8. doi: 10.1038/ajg.2009.369.
4
Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort.
Eur J Cancer Prev. 2009 Sep;18(5):381-4. doi: 10.1097/CEJ.0b013e32832e0955.
5
Risk factors for esophageal cancer development.
Surg Oncol Clin N Am. 2009 Jul;18(3):469-85. doi: 10.1016/j.soc.2009.03.005.
6
Role of obesity in Barrett's esophagus and cancer.
Surg Oncol Clin N Am. 2009 Jul;18(3):439-52. doi: 10.1016/j.soc.2009.03.010.
7
Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
Virchows Arch. 2009 Jun;454(6):629-37. doi: 10.1007/s00428-009-0769-z. Epub 2009 Apr 25.
10
Esophageal adenocarcinoma in "mice and men": back to basics!
Am J Gastroenterol. 2008 Sep;103(9):2367-72. doi: 10.1111/j.1572-0241.2008.02004.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验